Merck & Co., Inc. provided earnings guidance for the year 2022. For the year, the company expects Sales in the range of $56.9 to $58.1 billion, and EPS in the range of $5.90 to $6.02.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.5 USD | -0.58% | -2.80% | +16.97% |
05-02 | Merck: encouraging results in gastric cancer | CF |
05-01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.97% | 323B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co., Inc. Provides Earnings Guidance for the Year 2022